Documente Academic
Documente Profesional
Documente Cultură
clulas NK por
degranulacin frente a
melanoma.
Autores: Jose Antonio Cspedes Lagos, Ariana Joshkel Lima Ortiz
iiArnon TI, Markel G, Mandelboim O: Tumor and viral recognition by natural killer cells
receptors. Semin Cancer Biol 2006;16:348 358.
iii Ljunggren HG, Karre K: In search of the missing self: MHC molecules and NK cell
recognition. Immunol Today 1990;11:237 244.
iv Long EO: Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol
Rev 2008;224:7084.
v Farag SS, Caligiuri MA: Human natural killer cell development and biology. Blood Rev
2006;20:123137.
vi
vii Lee JA: The determination of melanoma stage at diagnosis. Dermatol Res Pract
2010; 839829:13.
ix Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S. Revving up natural killer cells and
cytokine-induced killer cells against hematological malignancies. Front
Immunol (2015) 6:230.10.3389/fimmu.2015.00230
x Holsken O, Miller M, Cerwenka A. Exploiting natural killer cells for therapy of melanoma. J Dtsch
Dermatol Ges (2015) 13:238.10.1111/ddg.12557
xi Mendez R, Aptsiauri N, Del CA, Maleno I, Cabrera T, Ruiz-Cabello F, et al. HLA and melanoma:
multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB
cell bank. Cancer Immunol Immunother (2009) 58:150715.10.1007/s00262-009-0701-z
xii Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman
D, Ferrone S, Moretta L, Moretta A: Major histocompatibility complex class I-related
chain A and UL16-binding protein expression on tumor cell lines of different histotypes:
analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Cancer Res 2002;62:61786186.
xiii Hecht ML, Rosental B, Horlacher T, Hershkovitz O, De Paz JL, Noti C, Schauer S,
Porgador A, Seeberger PH: Natural cytotoxicity receptors NKp30, NKp44 and NKp46
bind to different heparan sulfate/heparin sequences. J Proteome Res 2009;8:712720
xiv Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 3:3856
93.10.3390/cancers3043856
xv
xvi West EJ, Scott KJ, Jennings VA, Melcher AA. Immune activation by combination human
lymphokine-activated killer and dendritic cell therapy. Br J Cancer (2011) 105:787
95.10.1038/bjc.2011.290
xviii Suerth JD, Morgan MA, Kloess S, Heckl D, Neudorfl C, Falk CS, et al. Efficient generation of
gene-modified human natural killer cells via alpharetroviral vectors. J Mol
Med (2015).10.1007/s00109-015-1327-6
xix erme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1-
dependent immunosuppression in cancer. Cancer Res (2011) 71:53939.10.1158/0008-
5472.CAN-11-0993
xx Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell
activity. Front Immunol (2015) 6:195.10.3389/fimmu.2015.00195
xxi Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 3:3856
93.10.3390/cancers3043856